Skip to main content

Table 1 The baseline characteristics of included studies

From: Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

AuthorYearPublication typeSource of analyzed dataCountryCancer typeSample sizeImmunotherapy regimenBMI stratificationOutcomes
Ichihara (cohort 1)2020Full textRetrospective cohortJapanNSCLC84Cohort1: pembrolizumabHigh: ≥ 22.0; low: < 22.0OS, PFS
Ichihara (Cohort 2)2020Full textRetrospective cohortJapanNSCLC429Cohort2: nivolumab, pembrolizumab, atezolizumabHigh: ≥ 22.0; low: < 22.0OS, PFS
Popinat2019Full textRetrospective cohortFranceNSCLC55NivolumabHigh: ≥ 24.7; low: < 24.7OS
Magri2019Full textRetrospective cohortIsraelNSCLC46NivolumabHigh: ≥ 24.6; low: < 24.6OS
Kulkarni2019AbstractRetrospective cohortUSANSCLC148NivolumabHigh: ≥ 25.0; low: < 25.0OS, PFS
Kichenadasse2019Full textNCT02031458 NCT01846416USA, AustraliaNSCLC1434AtezolizumabNormal: 18.5–24.9 overweight: 25.0–29.9 obese: ≥ 30OS, PFS, IRAEs
Zhi2018AbstractRetrospective cohortUSANSCLC703Nivolumab, pembrolizumabNormal: 18.5–24.9; overweight: 25.0–29.9; obese: ≥ 30OS, PFS
Wang2019Full textRetrospective cohortUSANSCLC Melanoma OC250PD-L1 inhibitorHigh: ≥ 30; low: < 30OS, PFS
Cortellini2019Full textRetrospective cohortItalyNSCLC RCC melanoma976Pembrolizumab, nivolumab, atezolizumabDefinition1: high: ≥ 25.0; low: < 25.0 definition2: Normal: 18.5–24.9; overweight: 25·0–29.9; Obese: ≥ 30OS, PFS, IRAEs
Naik2019Full textRetrospective cohortUSAMelanoma139PD-1 inhibitorHigh: 25.0–35 low: < 25OS, PFS
Richtig2018Full textRetrospective cohortAustriaMelanoma76IpilimumabHigh: ≥ 25.0; Low: < 25.0OS, PFS
McQuade (cohort 1)2018Full textNCT00324155& retrospective corhotUSA, AustraliaMelanoma207Cohort 1:
Ipilimumab plus dacarbazine
Normal: 18.5–24.9; overweight: 25.0–29.9; Obese: ≥ 30OS, PFS, IRAEs
McQuade (Cohort 2)2018Full textNCT00324155& Retrospective corhotUSA, AustraliaMelanoma329Cohort 2: Pembrolizumab, nivolumab, atezolizumabNormal: 18.5–24.9; Overweight: 25.0–29.9; Obese: ≥ 30OS, PFS, IRAEs
Labadie2019Full textRetrospective cohortUSA, Canada, SpainRCC90Pembrolizumab, nivolumab, atezolizumabNormal: 18.5–24.9
Overweight: 25.0–29.9 Obese: ≥ 30
OS, PFS
De Giorgi2019Full textRetrospective cohortItalyRCC313Nivolumabhigh: ≥ 25.0; low: < 25.0OS
  1. NSCLC, non-small cell lung cancer; RCC, renal cell cancer; OC, ovarian cancer; BMI, Body mass index; OS, overall survival; PFS, progression-free survival; IRAEs, immune-related adverse effects